Stay updated with breaking news from Abivax. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
15.11.2022 - EQS-News: ABIVAX / Key word(s): AGM/EGM Abivax releases the results of its November 9, 2022 ad hoc ordinary and extraordinary general meeting 15.11.2022 / 18:00 CET/CEST The issuer is solely responsible for the content of this announcement. ABIVAX ...
First patient enrolled into the global phase 3 program with obefazimod ("ABTECT-Program") for the treatment of moderate to severe ulcerative colitis (UC) in the US1,200 UC patients across 36 countries
Abivax abstract on obefazimod phase 2b results selected for moderated poster presentation at UEG Week 2022Obefazimod (ABX464) interim 48-week safety and efficacy analysis from the ongoing phase 2b maintenance
06.09.2022 - Phase 2b induction trial and 48-week extension results of obefazimod in ulcerative colitis (UC) published in the prestigious, peer-reviewed journal 'The Lancet Gastroenterology & Hepatology'Scientific community validates the capacity of obefazimod ... Seite 1
DGAP-News: ABIVAX / Key word(s): Miscellaneous Abivax publishes a prospectus in the context of its capital increase 02.09.2022 / 20:40 CET/CEST The issuer is solely responsible for